Biomedicine & Pharmacotherapy最新文献

{"title":"Retraction notice to \"Acute myocardial infarction therapy using calycosin and tanshinone co-loaded mitochondria targeted lipid-polymer hybrid nano-system: Preparation, characterization, and anti myocardial infarction activity assessment\" [Biomed. Pharmacother. 155 (2022) 113650]","authors":"Jieke Yan , Jing Guo , Yuzhen Wang , Xiaowei Xing , Xuguang Zhang , Guanghao Zhang , Zhaoqiang Dong","doi":"10.1016/j.biopha.2026.119224","DOIUrl":"10.1016/j.biopha.2026.119224","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119224"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147476488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Investigation of prunetrin induced G2/M cell cycle arrest and apoptosis via Akt/mTOR/MAPK pathways in hepatocellular carcinoma cells” [Biomed. Pharmacother. 174 (2024) 116483]","authors":"Abuyaseer Abusaliya , Pritam Bhagwan Bhosale , Hun Hwan Kim , Min Yeong Park , Se Hyo Jeong , Sijoon Lee , Gon Sup Kim","doi":"10.1016/j.biopha.2026.119203","DOIUrl":"10.1016/j.biopha.2026.119203","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119203"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147476497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceftriaxone administration reduces vascular calcification associated with experimental models of chronic kidney disease","authors":"Teresa Obrero Sojo ,&nbsp;Ma José Jiménez Moral ,&nbsp;Fátima Guerrero Pavón ,&nbsp;Ma Encarnación Rodríguez Ortiz ,&nbsp;Ana Isabel Torralbo ,&nbsp;Karen Valdés Díaz ,&nbsp;Raquel Ma García Sáez ,&nbsp;Antonio Domínguez Rivas ,&nbsp;Daniel Jurado Montoya ,&nbsp;Fernando Leiva-Cepas ,&nbsp;Ma Victoria Pendón Ruiz de Mier ,&nbsp;Cristian Rodelo Haad ,&nbsp;Griet Glorieux ,&nbsp;Mariano Rodríguez ,&nbsp;Sagrario Soriano Cabrera ,&nbsp;Juan Rafael Muñoz Castañeda","doi":"10.1016/j.biopha.2026.119131","DOIUrl":"10.1016/j.biopha.2026.119131","url":null,"abstract":"<div><div>Gut microbiota dysbiosis has been implicated in systemic inflammation, potentially exacerbating chronic kidney disease (CKD) and vascular calcification (VC). The effects of gut microbiota depletion on VC using antibiotics remain largely unknown. We investigated the role of microbiota depletion in chronic and acute experimental models of CKD and VC in Wistar rats. The chronic CKD model consisted of 5/6 nephrectomy (Nx), a moderate-phosphate diet (0.9 %), and intraperitoneal injections of calcitriol (25 ng/kg i.p every 48 h) for 30 days. For the following 15 days, dietary phosphate was increased to 1.2 %, and calcitriol at 40 ng/kg i.p every 48 h. In the acute VC model, a high-phosphate diet (1.2 %) and calcitriol (60 ng/kg every 48 h) were administered for 14 days after the Nx. In both models, half of the animals received oral ceftriaxone (ATB, 400 mg/kg/day) for seven days prior to Nx. Parameters related to mineral metabolism, kidney function, bone histomorphometry and mineralization, VC, calcification-related signaling pathways, uremic toxins, and fecal microbiota composition and functional inference were analysed. Antibiotic-treated rats showed significantly lower serum phosphate levels, reduced uremic toxins, and decreased VC with no effects on bone turnover. Colidextribacter and Escherichia-Shigella were positively correlated with serum phosphate levels. Interestingly, Ceftriaxone treatment reduced the abundance of such genera. Additionally, the abundance of Colidextribacter also correlated with calcium content in the thoracic aorta. In conclusion, microbiota depletion by ceftriaxone reduced hyperphosphatemia and VC in experimental CKD and VC models. These findings support the potential of targeting the gut microbiota as a novel strategy to mitigate mineral metabolism disturbances and VC in CKD.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119131"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents","authors":"Marianna Grignolo ,&nbsp;Andrea Spinaci ,&nbsp;Ludovica Ricci ,&nbsp;Anna Pegoraro ,&nbsp;Luigia Ruo ,&nbsp;Catia Lambertucci ,&nbsp;Daniele Vitone ,&nbsp;Marcello Leopoldo ,&nbsp;Enza Lacivita ,&nbsp;Federica Fortuna ,&nbsp;Michela Buccioni ,&nbsp;Beatrice Francucci ,&nbsp;Gabriella Marucci ,&nbsp;Diego Dal Ben ,&nbsp;Rosaria Volpini ,&nbsp;Elena Adinolfi","doi":"10.1016/j.biopha.2026.119185","DOIUrl":"10.1016/j.biopha.2026.119185","url":null,"abstract":"<div><div>Extracellular ATP is a key component of the tumor microenvironment, where it promotes cancer progression by activating the P2X7 receptor (P2X7R). Prolonged receptor stimulation triggers the release of pro-tumorigenic extracellular vesicles and soluble factors, including IL-1β, VEGF, and TGFβ. Here, we report the design and characterization of novel triazole- and benzamide-based negative allosteric modulators of P2X7R. Among these, compounds <strong>5</strong> and <strong>9</strong> showed nanomolar affinity for the human receptor (<em>K</em>_i = 80 nM and 3.17 nM, respectively) and effectively inhibited calcium influx (IC₅₀ 370 nM and 47 nM, respectively). Molecular docking supported distinct binding modes for the two scaffolds, aligning them with known allosteric inhibitors through interactions with Lys297, Asp92, and hydrophobic subpockets. Compounds <strong>5</strong> and <strong>9</strong> displayed favorable metabolic stability in mouse liver microsomes and efficiently blocked P2X7R-dependent signaling in melanoma, glioblastoma, and colon carcinoma cells. Treatment with both compounds significantly reduced tumor cell proliferation, invasiveness, and extracellular vesicle release, with efficacy comparable to or greater than that of the reference antagonist A740003. In vivo, both molecules suppressed melanoma growth in syngeneic mice and modulated cytokine levels in the TME by increasing IFN-γ while reducing VEGF, IL-1β, and TGF-β. These findings identify compounds <strong>5</strong> and <strong>9</strong> as potent, selective, and metabolically stable P2X7R antagonists with translational potential as anticancer agents targeting both tumor growth and extracellular vesicle-mediated communication.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119185"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147387417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human VH-antibody-based CAR T cells targeting folate receptor-alpha show enhanced persistence and reduced T-cell exhaustion against ovarian cancer","authors":"Nithidol Sakunrangsit ,&nbsp;Kannika Khantasup ,&nbsp;Natapol Pornputtipong ,&nbsp;Koramit Suppipat ,&nbsp;Nattiya Hirankarn ,&nbsp;Supannikar Tawinwung","doi":"10.1016/j.biopha.2026.119169","DOIUrl":"10.1016/j.biopha.2026.119169","url":null,"abstract":"<div><h3>Background</h3><div>Folate receptor-alpha (FOLR1) is highly expressed in ovarian cancer and correlates with poor clinical outcomes, making it an attractive target for adoptive cell therapy. Single-domain antibodies (V_H domains) have gained increasing interest as antigen-binding domains for CAR T-cell engineering.</div></div><div><h3>Methods</h3><div>We generated a second-generation FOLR1-specific CAR incorporating a fully human V_H-only antibody and compared its <em>in vitro</em> functional activity with a MOv19-derived scFV CAR. CAR expression, memory phenotype, cytotoxicity, cytokine secretion, and exhaustion markers were evaluated following antigen stimulation. Antitumor efficacy was further assessed in 3D spheroids and repeated tumor-rechallenge assays.</div></div><div><h3>Results</h3><div>Both V_H-based and scFV-based FOLR1 CAR T cells demonstrated potent and antigen-specific cytotoxicity against FOLR1-positive ovarian cancer cells. Intriguingly, FOLR1-V_H CAR T cells showed lower activation and cytokine release upon initial stimulation, accompanied by reduced expression of exhaustion markers including PD-1 and LAG-3. FOLR1-V_H CAR T cells preferentially preserved a central-memory phenotype and displayed superior persistence and tumor control during multiple rounds of antigen rechallenge. Both CAR formats achieved comparable cytotoxicity in 3D spheroid models.</div></div><div><h3>Conclusion</h3><div>Human FOLR1-V_H CAR T cells demonstrated potent antitumor activity with reduced exhaustion and enhanced persistence. These properties highlight the V_H domain as a promising targeting module for next-generation CAR T-cell therapies in ovarian cancer.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119169"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Nanoparticles as an effective drug delivery system in COVID-19\" [Biomedicine & Pharmacotherapy 143 (2021) 112162]","authors":"Neehasri Kumar Chowdhury ,&nbsp;Deepika ,&nbsp;Reshma Choudhury ,&nbsp;Gaurav Ambadas Sonawane ,&nbsp;Shankar Mavinamar ,&nbsp;Xiaoming Lyu ,&nbsp;Ramendra Pati Pandey ,&nbsp;Chung-Ming Chang","doi":"10.1016/j.biopha.2026.119150","DOIUrl":"10.1016/j.biopha.2026.119150","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119150"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146777076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"ATP ion channel P2X purinergic receptors in inflammation response\" [Biomedicine & Pharmacotherapy 158 (2023) 114205]","authors":"Ji-peng Liu ,&nbsp;Si-cheng Liu ,&nbsp;Shi-qi Hu ,&nbsp;Jia-feng Lu ,&nbsp;Chang-lei Wu ,&nbsp;Dong-xia Hu ,&nbsp;Wen-jun Zhang","doi":"10.1016/j.biopha.2026.119148","DOIUrl":"10.1016/j.biopha.2026.119148","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119148"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Narciclasine suppresses oral cancer metastasis by modulating cathepsin B and extracellular signal-related kinase pathways” [Biomed. Pharmacother. 158 (2023) 114159]","authors":"Mu-Kuei Shieu ,&nbsp;Hsin-Yu Ho ,&nbsp;Chia-Chieh Lin ,&nbsp;Yu-Sheng Lo ,&nbsp;Yi-Ching Chuang ,&nbsp;Ming-Ju Hsieh ,&nbsp;Mu-Kuan Chen","doi":"10.1016/j.biopha.2026.119189","DOIUrl":"10.1016/j.biopha.2026.119189","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119189"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Diclofenac and metformin synergistic dose dependent inhibition of hamster fibrosarcoma, rescued with mebendazole” [Biomedicine & Pharmacotherapy 167 (2023) 115528]","authors":"Dušica J. Popović ,&nbsp;Kosta J. Popović ,&nbsp;Dejan Miljković ,&nbsp;Jovan K. Popović ,&nbsp;Dušan Lalošević ,&nbsp;Mihalj Poša ,&nbsp;Zana Dolićanin ,&nbsp;Ivan Čapo","doi":"10.1016/j.biopha.2026.119194","DOIUrl":"10.1016/j.biopha.2026.119194","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119194"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Adult hippocampal neurogenesis (AHN) controls central nervous system and promotes peripheral nervous system regeneration via physical exercise\" [Biomedicine & Pharmacotherapy 165 (2023) 115078]","authors":"Vahideh Zalouli ,&nbsp;Hosnieh Rajavand ,&nbsp;Mahdi Bayat ,&nbsp;Jalil Khaleghnia ,&nbsp;Fariborz Sharifianjazi ,&nbsp;Farzad Jafarinazhad ,&nbsp;Nima Beheshtizadeh","doi":"10.1016/j.biopha.2026.119212","DOIUrl":"10.1016/j.biopha.2026.119212","url":null,"abstract":"","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":"197 ","pages":"Article 119212"},"PeriodicalIF":7.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147461393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}